In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006.


No information is available on the clinical use of acamprosate during breastfeeding. Based on its chemical properties it is likely to enter milk. However, the oral bioavailability of acamprosate is only 11%, so systemic effects in the breastfed infant are unlikely. If acamprosate is required by the mother, it is not a reason to discontinue breastfeeding. Monitor the breastfed infant for diarrhea.

Publication types

  • Review